Drug Details
| General Information of the Drug (ID: DR7504) | ||||
|---|---|---|---|---|
| Name |
GW9662
|
|||
| Synonyms |
GW9662; 22978-25-2; 2-Chloro-5-nitro-N-phenylbenzamide; GW 9662; 2-Chloro-5-nitrobenzanilide; GW-9662; benzamide, 2-chloro-5-nitro-N-phenyl-; UNII-UM18UZV2YD; MFCD01215270; UM18UZV2YD; MLS001056751; CHEBI:79993; 2-Chloro-5-nitro-N-phenyl-benzamide; 2-Chloro-5-nitro- N -phenylbenzamide; 2-Chloro-5-nitro-N-4-phenylbenzamide; SMR000326735; (2-chloro-5-nitrophenyl)-N-benzamide; SR-01000075999; Benzamide,2-chloro-5-nitro-N-phenyl-; Tocris-1508; Spectrum5_001989; Lopac-M-6191; DSSTox_CID_20723; DSSTox_RID_79570; DSSTox_GSID_40723; Lopac0_000798; BSPBio_001021; KBioGR_000361; KBioSS_000361; SCHEMBL420231; CHEMBL375270; cid_644213; GTPL3442; DTXSID8040723; BCBcMAP01_000086; BDBM55936; KBio2_000361; KBio2_002929; KBio2_005497; KBio3_000701; KBio3_000702; ZINC39173; EX-A595; Bio2_000341; Bio2_000821; HMS1362C03; HMS1792C03; HMS1990C03; HMS2235C11; HMS3262O18; HMS3267P20; HMS3372P17; HMS3403C03; HMS3412F15; HMS3649C18; HMS3651L10; HMS3676F15; AOB31774; BCP06354; 2-Chloro-5-nitrobenzanilide, 97%; METHYL15-METHYLHEPTADECANOATE; Tox21_301993; Tox21_500798; s2915; SBB006523; STL260137; AKOS000155195; CCG-204882; CS-1102; DB07863; LP00798; MCULE-8174475490; SDCCGSBI-0050775.P002; 2-chloranyl-5-nitro-N-phenyl-benzamide; IDI1_002096; Benzanilide, 2-chloro-5-nitro- (8CI); NCGC00015688-01; NCGC00015688-02; NCGC00015688-03; NCGC00015688-04; NCGC00015688-05; NCGC00015688-06; NCGC00015688-07; NCGC00015688-08; NCGC00015688-09; NCGC00015688-21; NCGC00025193-01; NCGC00025193-02; NCGC00025193-03; NCGC00025193-04; NCGC00025193-05; NCGC00025193-06; NCGC00025193-07; NCGC00255683-01; NCGC00261483-01; AC-31443; AK173264; AS-14069; GW9662, >98% (HPLC); HY-16578; ST055753; SY040458; AB0109180; CAS-22978-25-2; EU-0100798; FT-0664839; SW203813-2; Z6199; EC-000.2405; A11984; Benzamide, 2-chloro-5-nitro-N-phenyl- (9CI); C15627; J90030; M 6191; S-7731; J-014928; SR-01000075999-1; SR-01000075999-3; SR-01000075999-6; SR-01000075999-9; BRD-K93258693-001-02-5; BRD-K93258693-001-05-8; Q27077962; Z27782632
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Breast cancer [ICD-11: 2C60] | Investigative | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C13H9ClN2O3
|
|||
| PubChem CID | ||||
| Canonical SMILES |
C1=CC=C(C=C1)NC(=O)C2=C(C=CC(=C2)[N+](=O)[O-])Cl
|
|||
| InChI |
1S/C13H9ClN2O3/c14-12-7-6-10(16(18)19)8-11(12)13(17)15-9-4-2-1-3-5-9/h1-8H,(H,15,17)
|
|||
| InChIKey |
DNTSIBUQMRRYIU-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 22978-25-2
|
|||
| ChEBI ID | ||||
| TTD Drug ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Gamma tocotrienol | Bixa orellana | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CDK4 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDK6 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | HPGDS | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| MDA-231 | Breast cancer | Homo sapiens | ||||
| Neoplastic +SA cells derived from a mammary adenocarcinoma | Mammary Adenocarcinoma | Homo sapiens | ||||
| Experimental
Result(s) |
Combined Gamma -tocotrienol and PPAR Gamma antagonists treatment in PPAR Gamma negative/silenced breast cancer cells are mediated through PPAR Gamma -independent mechanisms that are associated with a downregulation in COX-2, PGDS, and PGD2 synthesis. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | PPAR-gamma (PPARG) | Molecule Info | [3] | |
| Retinoic acid receptor RXR-alpha (RXRA) | Molecule Info | [3] | ||
| KEGG Pathway | PPAR signaling pathway | Click to Show/Hide | ||
| 2 | PI3K-Akt signaling pathway | |||
| 3 | Thyroid hormone signaling pathway | |||
| 4 | Adipocytokine signaling pathway | |||
| 5 | Non-alcoholic fatty liver disease (NAFLD) | |||
| 6 | Bile secretion | |||
| 7 | Hepatitis C | |||
| 8 | Pathways in cancer | |||
| 9 | Transcriptional misregulation in cancer | |||
| 10 | Thyroid cancer | |||
| 11 | Small cell lung cancer | |||
| 12 | Non-small cell lung cancer | |||
| 13 | AMPK signaling pathway | |||
| 14 | Osteoclast differentiation | |||
| 15 | Huntington's disease | |||
| NetPath Pathway | IL1 Signaling Pathway | Click to Show/Hide | ||
| 2 | TGF_beta_Receptor Signaling Pathway | |||
| 3 | Leptin Signaling Pathway | |||
| Panther Pathway | Vitamin D metabolism and pathway | Click to Show/Hide | ||
| 2 | CCKR signaling map ST | |||
| Pathway Interaction Database | Regulation of Androgen receptor activity | Click to Show/Hide | ||
| 2 | RXR and RAR heterodimerization with other nuclear receptor | |||
| 3 | Retinoic acid receptors-mediated signaling | |||
| 4 | a6b1 and a6b4 Integrin signaling | |||
| 5 | Noncanonical Wnt signaling pathway | |||
| 6 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
| 7 | Signaling events mediated by HDAC Class I | |||
| 8 | Regulation of retinoblastoma protein | |||
| Reactome | RORA activates gene expression | Click to Show/Hide | ||
| 2 | BMAL1:CLOCK,NPAS2 activates circadian gene expression | |||
| 3 | Recycling of bile acids and salts | |||
| 4 | PPARA activates gene expression | |||
| 5 | Import of palmitoyl-CoA into the mitochondrial matrix | |||
| 6 | YAP1- and WWTR1 (TAZ)-stimulated gene expression | |||
| 7 | Regulation of pyruvate dehydrogenase (PDH) complex | |||
| 8 | Endogenous sterols | |||
| 9 | Transcriptional activation of mitochondrial biogenesis | |||
| 10 | Activation of gene expression by SREBF (SREBP) | |||
| 11 | Transcriptional regulation of white adipocyte differentiation | |||
| 12 | Nuclear Receptor transcription pathway | |||
| 13 | Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||
| 14 | Circadian Clock | |||
| WikiPathways | Vitamin A and Carotenoid Metabolism | Click to Show/Hide | ||
| 2 | NRF2 pathway | |||
| 3 | Nuclear Receptors Meta-Pathway | |||
| 4 | Farnesoid X Receptor Pathway | |||
| 5 | PPAR Alpha Pathway | |||
| 6 | Vitamin D Receptor Pathway | |||
| 7 | Pregnane X Receptor pathway | |||
| 8 | Constitutive Androstane Receptor Pathway | |||
| 9 | Liver X Receptor Pathway | |||
| 10 | Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||
| 11 | Transcriptional Regulation of White Adipocyte Differentiation | |||
| 12 | YAP1- and WWTR1 (TAZ)-stimulated gene expression | |||
| 13 | Activation of Gene Expression by SREBP (SREBF) | |||
| 14 | Integrated Pancreatic Cancer Pathway | |||
| 15 | Adipogenesis | |||
| 16 | Circadian Clock | |||
| 17 | Nuclear Receptors | |||
| 18 | Vitamin D Metabolism | |||
| 19 | Wnt Signaling Pathway Netpath | |||
| 20 | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
| 21 | Differentiation of white and brown adipocyte | |||
| 22 | SREBP signalling | |||
